drugset / Trial / NCT00965094

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

NCT00965094

Phase 4 Completed 36 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this trial is to show non-inferiority of a CNI-free regimen with respect to the renal function at Month 9 post Tx assessed by glomerular filtration rate - Nankivell method - as compared to the standard CNI-based regimen in de novo renal transplant patients.

Timeline

Start
2009-12
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 2 mg
Comparator Tacrolimus Small molecule
Background Basiliximab Monoclonal antibody 20 mg Intravenous
Background Mycophenolate Sodium Unknown 1440 mg
Background Prednisone Other / unclassified 5 mg